Sign inJoin waitlistJoin the waitlist

Ryan Cassaday

Professor, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
2010–2013
Internal Medicine
University of Wisconsin Hospitals and Clinics
2007–2010
University of Wisconsin School of Medicine and Public Health
2003–2007

Research

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
The Lancet · 2021 · 704 citations
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Nature Medicine · 2004 · 562 citations
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Blood · 2014 · 391 citations

Ajay Gopal
34 papers
Brian Till
26 papers
David Maloney
24 papers
Mazyar Shadman
21 papers
Daniel DeAngelo
19 papers
Anjali Advani
18 papers
Damian Green
18 papers
AS
Andrei Shustov
17 papers
Mary-Elizabeth Percival
17 papers
NK
Noam Kopmar
16 papers
Stephen Smith
16 papers
BS
Bijal Shah
15 papers

Clinical trials

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Principal investigator · Recruiting · Phase 2
University of Washington
2026–2028
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Principal investigator · Recruiting · Phase 2
University of Washington
2026–2028
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Principal investigator · Active not recruiting · Phase 2
University of Washington
2023–2031
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Principal investigator · Completed · Phase 1
University of Washington
2019–2023